Vertex Historical Cash Flow

VRTX Stock

USD 469.22 4.76 1.00%

Analysis of Vertex Pharmaceuticals cash flow over time is an excellent tool to project Vertex Pharmaceuticals future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Free Cash Flow of 3.4 B or Begin Period Cash Flow of 11 B as it is a great indicator of Vertex Pharmaceuticals ability to facilitate future growth, repay debt on time or pay out dividends.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Vertex Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Vertex Pharmaceuticals is a good buy for the upcoming year.

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vertex Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.

About Vertex Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in Vertex balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Vertex's non-liquid assets can be easily converted into cash.

Vertex Pharmaceuticals Cash Flow Chart

At this time, Vertex Pharmaceuticals' Cash And Cash Equivalents Changes is fairly stable compared to the past year. Change To Operating Activities is likely to rise to about 863.4 M in 2024, despite the fact that Change In Cash is likely to grow to (132.7 M).

Capital Expenditures End Period Cash Flow Change To Liabilities Stock Based Compensation Cash Flows Other Operating

Capital Expenditures

Capital Expenditures are funds used by Vertex Pharmaceuticals to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Vertex Pharmaceuticals operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Most accounts from Vertex Pharmaceuticals' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Vertex Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vertex Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.At this time, Vertex Pharmaceuticals' Cash And Cash Equivalents Changes is fairly stable compared to the past year. Change To Operating Activities is likely to rise to about 863.4 M in 2024, despite the fact that Change In Cash is likely to grow to (132.7 M).

	2021	2022	2023	2024 (projected)
Capital Expenditures	235M	204.7M	258.4M	271.3M
Depreciation	125.6M	148.3M	181.3M	190.4M

Capital Expenditures Depreciation

Vertex Pharmaceuticals cash flow statement Correlations

	Change In Cash	Free Cash Flow	Change In Working Capital	Begin Period Cash Flow	Depreciation	Capital Expenditures	Net Income	End Period Cash Flow	Other Non Cash Items	Change To Liabilities	Change To Account Receivables	Stock Based Compensation	Change To Inventory	Sale Purchase Of Stock	Dividends Paid	Investments	Change Receivables	Net Borrowings	Exchange Rate Changes	Cash And Cash Equivalents Changes	Cash Flows Other Operating	Change To Netincome	Change To Operating Activities	Issuance Of Capital Stock
Change In Cash		0.56	0.62	0.16	0.28	0.37	0.46	0.42	-0.19	0.33	-0.73	0.36	-0.09	-0.33	0.35	0.38	-0.46	-0.17	-0.39	0.4	-0.31	0.15	0.3	0.27
Free Cash Flow	0.56		-0.01	0.88	0.89	0.81	0.97	0.96	-0.38	0.91	-0.67	0.91	-0.79	-0.67	0.47	-0.49	-0.89	-0.3	-0.62	0.91	-0.4	0.28	0.89	0.88
Change In Working Capital	0.62	-0.01		-0.3	-0.22	-0.21	-0.05	-0.11	0.19	-0.16	-0.21	-0.15	0.48	0.16	-0.08	0.54	0.15	0.13	-0.04	-0.14	-0.43	0.03	-0.07	-0.32
Begin Period Cash Flow	0.16	0.88	-0.3		0.95	0.76	0.89	0.96	-0.31	0.95	-0.41	0.91	-0.91	-0.58	0.32	-0.79	-0.83	-0.24	-0.53	0.91	-0.29	0.22	0.94	0.88
Depreciation	0.28	0.89	-0.22	0.95		0.78	0.89	0.95	-0.36	0.91	-0.52	0.98	-0.89	-0.61	0.2	-0.66	-0.86	-0.32	-0.62	0.9	-0.32	0.27	0.93	0.89
Capital Expenditures	0.37	0.81	-0.21	0.76	0.78		0.78	0.8	-0.12	0.78	-0.5	0.84	-0.77	-0.6	0.3	-0.5	-0.73	-0.55	-0.25	0.77	-0.31	0.51	0.72	0.7
Net Income	0.46	0.97	-0.05	0.89	0.89	0.78		0.95	-0.44	0.9	-0.6	0.91	-0.81	-0.7	0.47	-0.57	-0.88	-0.26	-0.68	0.91	-0.52	0.19	0.92	0.85
End Period Cash Flow	0.42	0.96	-0.11	0.96	0.95	0.8	0.95		-0.34	0.96	-0.57	0.93	-0.86	-0.62	0.39	-0.62	-0.89	-0.27	-0.6	0.95	-0.35	0.24	0.95	0.89
Other Non Cash Items	-0.19	-0.38	0.19	-0.31	-0.36	-0.12	-0.44	-0.34		-0.3	0.41	-0.37	0.31	0.45	-0.43	0.08	0.48	-0.28	0.84	-0.32	-0.04	0.65	-0.32	-0.46
Change To Liabilities	0.33	0.91	-0.16	0.95	0.91	0.78	0.9	0.96	-0.3		-0.44	0.89	-0.91	-0.43	0.38	-0.72	-0.83	-0.29	-0.5	0.98	-0.34	0.22	0.97	0.83
Change To Account Receivables	-0.73	-0.67	-0.21	-0.41	-0.52	-0.5	-0.6	-0.57	0.41	-0.44		-0.59	0.35	0.62	-0.2	-0.19	0.82	0.39	0.59	-0.43	0.2	-0.05	-0.46	-0.53
Stock Based Compensation	0.36	0.91	-0.15	0.91	0.98	0.84	0.91	0.93	-0.37	0.89	-0.59		-0.85	-0.66	0.2	-0.59	-0.88	-0.4	-0.63	0.88	-0.41	0.31	0.92	0.86
Change To Inventory	-0.09	-0.79	0.48	-0.91	-0.89	-0.77	-0.81	-0.86	0.31	-0.91	0.35	-0.85		0.45	-0.19	0.79	0.8	0.44	0.44	-0.9	0.22	-0.2	-0.86	-0.83
Sale Purchase Of Stock	-0.33	-0.67	0.16	-0.58	-0.61	-0.6	-0.7	-0.62	0.45	-0.43	0.62	-0.66	0.45		-0.36	0.19	0.66	0.14	0.66	-0.44	0.34	-0.12	-0.46	-0.65
Dividends Paid	0.35	0.47	-0.08	0.32	0.2	0.3	0.47	0.39	-0.43	0.38	-0.2	0.2	-0.19	-0.36		-0.14	-0.32	0.4	-0.3	0.41	-0.06	-0.08	0.27	0.41
Investments	0.38	-0.49	0.54	-0.79	-0.66	-0.5	-0.57	-0.62	0.08	-0.72	-0.19	-0.59	0.79	0.19	-0.14		0.39	0.15	0.16	-0.67	0.18	-0.2	-0.7	-0.61
Change Receivables	-0.46	-0.89	0.15	-0.83	-0.86	-0.73	-0.88	-0.89	0.48	-0.83	0.82	-0.88	0.8	0.66	-0.32	0.39		0.4	0.67	-0.8	0.27	-0.11	-0.84	-0.85
Net Borrowings	-0.17	-0.3	0.13	-0.24	-0.32	-0.55	-0.26	-0.27	-0.28	-0.29	0.39	-0.4	0.44	0.14	0.4	0.15	0.4		-0.12	-0.28	0.16	-0.53	-0.29	-0.2
Exchange Rate Changes	-0.39	-0.62	-0.04	-0.53	-0.62	-0.25	-0.68	-0.6	0.84	-0.5	0.59	-0.63	0.44	0.66	-0.3	0.16	0.67	-0.12		-0.53	0.31	0.39	-0.58	-0.61
Cash And Cash Equivalents Changes	0.4	0.91	-0.14	0.91	0.9	0.77	0.91	0.95	-0.32	0.98	-0.43	0.88	-0.9	-0.44	0.41	-0.67	-0.8	-0.28	-0.53		-0.37	0.24	0.94	0.82
Cash Flows Other Operating	-0.31	-0.4	-0.43	-0.29	-0.32	-0.31	-0.52	-0.35	-0.04	-0.34	0.2	-0.41	0.22	0.34	-0.06	0.18	0.27	0.16	0.31	-0.37		-0.3	-0.47	-0.16
Change To Netincome	0.15	0.28	0.03	0.22	0.27	0.51	0.19	0.24	0.65	0.22	-0.05	0.31	-0.2	-0.12	-0.08	-0.2	-0.11	-0.53	0.39	0.24	-0.3		0.22	0.21
Change To Operating Activities	0.3	0.89	-0.07	0.94	0.93	0.72	0.92	0.95	-0.32	0.97	-0.46	0.92	-0.86	-0.46	0.27	-0.7	-0.84	-0.29	-0.58	0.94	-0.47	0.22		0.82
Issuance Of Capital Stock	0.27	0.88	-0.32	0.88	0.89	0.7	0.85	0.89	-0.46	0.83	-0.53	0.86	-0.83	-0.65	0.41	-0.61	-0.85	-0.2	-0.61	0.82	-0.16	0.21	0.82

Click cells to compare fundamentals

Vertex Pharmaceuticals Account Relationship Matchups

Vertex Pharmaceuticals cash flow statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Change In Cash	462.4M	2.9B	811.2M	3.7B	(139.7M)	(132.7M)
Free Cash Flow	1.5B	3.0B	2.4B	3.9B	3.3B	3.4B
Change In Working Capital	(66.1M)	(54.5M)	(105.2M)	340.8M	(265.7M)	(252.4M)
Begin Period Cash Flow	2.7B	3.1B	6.0B	6.8B	10.5B	11.0B
Other Cashflows From Financing Activities	24.8M	276.4M	130.3M	186.3M	134.6M	91.7M
Depreciation	106.9M	109.5M	125.6M	148.3M	181.3M	190.4M
Capital Expenditures	75.5M	259.8M	235M	204.7M	258.4M	271.3M
Total Cash From Operating Activities	1.6B	3.3B	2.6B	4.1B	3.5B	3.7B
Net Income	1.2B	2.7B	2.3B	3.3B	3.6B	3.8B
Total Cash From Financing Activities	126.8M	(505.3M)	(1.5B)	(67.7M)	(562.2M)	(534.1M)
End Period Cash Flow	3.1B	6.0B	6.8B	10.5B	10.4B	10.9B
Other Non Cash Items	(176.2M)	(220.0M)	(5.8M)	103.4M	(42.6M)	(40.5M)
Change To Liabilities	188.1M	598.6M	354.1M	1.2B	1.3B	1.4B
Change To Account Receivables	(225.6M)	(223.4M)	(274.7M)	(358.6M)	(84.1M)	(88.3M)
Stock Based Compensation	360.5M	429.5M	441.4M	491.3M	581.2M	610.3M
Other Cashflows From Investing Activities	(1.2B)	(19.3M)	(77M)	(343.7M)	(309.3M)	(293.9M)
Change To Inventory	(64.0M)	(132.0M)	(92.8M)	(136.4M)	(322.9M)	(306.8M)
Total Cashflows From Investing Activities	(1.2B)	99.4M	(340.9M)	(321.1M)	(289.0M)	(274.5M)
Sale Purchase Of Stock	(192.0M)	(739.4M)	(1.6B)	(172M)	(427.6M)	(406.2M)
Dividends Paid	20.8M	10.0M	264.9M	102M	117.3M	123.2M
Investments	33.7M	378.5M	(28.9M)	227.3M	(2.1B)	(2.0B)
Change Receivables	(225.6M)	(223.4M)	(274.7M)	(358.6M)	(322.7M)	(306.6M)
Net Borrowings	(35.0M)	(29.0M)	(24.4M)	(85.5M)	(77.0M)	(73.1M)
Cash And Cash Equivalents Changes	460.8M	2.8B	824.6M	3.7B	4.3B	4.5B
Cash Flows Other Operating	5.2M	(332.2M)	(263.5M)	(453.2M)	(407.9M)	(387.5M)
Change To Netincome	381.9M	521.4M	452.7M	445.6M	512.4M	437.4M
Change To Operating Activities	246.3M	249.7M	230.4M	715M	822.3M	863.4M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Vertex Stock Analysis

When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Vertex Historical Cash Flow

About Vertex Cash Flow Analysis

Vertex Pharmaceuticals Cash Flow Chart

Capital Expenditures

Stock Based Compensation

Vertex Pharmaceuticals cash flow statement Correlations

Vertex Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Vertex Pharmaceuticals cash flow statement Accounts

Also Currently Popular

Additional Tools for Vertex Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Stock Based Compensation	+ 0.98	Depreciation
Cash And Cash Equivalents Changes	+ 0.98	Change To Liabilities
Net Income	+ 0.97	Free Cash Flow
Change To Operating Activities	+ 0.97	Change To Liabilities
End Period Cash Flow	+ 0.96	Free Cash Flow
End Period Cash Flow	+ 0.96	Begin Period Cash Flow

Change To Inventory	- 0.91	Change To Liabilities
Change To Inventory	- 0.91	Begin Period Cash Flow
Cash And Cash Equivalents Changes	- 0.9	Change To Inventory
Change Receivables	- 0.89	End Period Cash Flow
Change To Inventory	- 0.89	Depreciation
Change Receivables	- 0.89	Free Cash Flow